drugset / Trial / NCT01499433
Efficacy and Safety of Caspofungin for Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease
Phase 4
Unknown
40 enrolled
The First Affiliated Hospital of Guangzhou Medical University
Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
The investigators propose to study the efficacy and safety of three-week antifungal therapy with caspofungin in hospitalized patients with proven or probable IPA underlying chronic obstructive pulmonary disease.
Timeline
- Start
- 2012-01
- Primary completion
- 2014-09
- Completion
- 2014-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Caspofungin | Other / unclassified | 50 mg | Intravenous |